A federal judge ruled Musk's own tweets about retiring the Twitter brand are evidence that killed the iconic logo trademark.

The healthcare giant is doubling down on oncology, betting that targeted therapies and data will reshape how cancer drugs reach patients.

Hui Ka-yan's sentence closes a debt saga, but unease persists for private developers as state-owned rivals circle.

Apple's new iOS 27 feature pairs a primary iPhone with a companion device, so you can leave the expensive one at home.

The federal investigation could delay Tesla's robotaxi launch in Texas and Florida, where the Cybercab is set to pick up passengers without a steering wheel or pedals.

The OpenAI CEO's reaction to Apple's lawsuit reveals a bigger problem: California's ban on non-competes leaves companies with no choice but to sue after the fact.

Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

Ukraine's strikes have knocked out 40% of Russia's refining capacity, sending diesel prices to all-time highs and threatening global supply chains.

In a letter to customers, GoPro's CEO promises the business keeps its 'core DNA,' yet the deal is being framed around national security and the largest individual shareholder gets no mention.

Tokyo's $1.4 billion in subsidies aims to help Imabari and rivals decarbonize fleets and compete with China and South Korea.

A new comptroller report shows inequality widening in New York City, even as the ultrawealthy fund nearly half of all income tax.

Central banks are rethinking where gold is safe after Russia's assets were frozen, and the Dutch just made the biggest move yet.